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Baker-Polito Administration Signs Life Sciences Initiative 
Invests $473 million in capital authorization, extends and expands job-creating state 
tax credit to $150 million over five years 
 
BOSTON – Today, Governor Charlie Baker signed An Act providing continued 
investment in the life sciences industry in the Commonwealth to invest up to $623 
million in bond authorization and tax credits over five years in education, research 
and development, and workforce training. This legislation will serve to reinforce the 
Baker-Polito Administration’s commitment to leadership in the life sciences sector. 
The funding will continue to be managed by the Massachusetts Life Sciences Center 
(MLSC), which is co-chaired by Administration and Finance Secretary Michael 
Heffernan and Housing and Economic Development Secretary Jay Ash. 
 
The bill was signed into law at Bunker Hill Community College (BHCC), which has 
received grants to help establish a new biotechnology program, internship 
placements at 30 life sciences companies and training for low-income adults to 
pursue biomedical careers. 
  
“Reauthorizing the Mass Life Sciences Initiative will facilitate stronger public-private 
partnerships and strategic investments to train our workforce starting the classrooms 
and attract world-class companies to the Commonwealth,” said Governor Charlie 
Baker. “In partnership with the Legislature, our administration remains dedicated to 
generating economic growth and supplying researchers with the tools they need to 
create new advancements in medical care.”   
 
 
Governor Charlie Baker was joined by Administration and Finance Secretary Michael 
Heffernan, legislative leaders, BHCC President Pam Y. Eddinger, PhD, President and 
CEO of the Massachusetts Biotechnology Council Robert Coughlin, President of the 
Dana-Farber Cancer Institute Laurie H. Glimcher, MD, Executive Vice President and 
Head of Sanofi Genzyme Bill Sibold and other life sciences stakeholders.  
 
“Massachusetts is home to a world-class talent pool and this legislation will ensure 
more educational and career opportunities for residents throughout every region of 
the Commonwealth,” said Lieutenant Governor Karyn Polito. “Our administration 
has made strategic workforce investments to educate, train and employ those 
interested in a career in the life sciences, empowering the Commonwealth to 
continue to lead the way in this field.” 
 
“Our state’s decision ten years ago to invest in life sciences research made 
Massachusetts a global leader in an industry that is inventing the future, and this 
legislation recommits us to that leadership,” said Senator Eric P. Lesser, Senate Chair 
of the Committee on Economic Development and Emerging Technologies. “This 
legislation also spreads out the growth we have seen in the biotech industry across 
the state, to regions that have manufacturing capacity but need targeted investments 
to gain access to these high-paying jobs. We want the next vaccine breakthrough, the 
next big discovery, the next lifesaving drug, to be developed here in Massachusetts. 
These investments in research and workforce training in the life sciences make that 
possible.” 
 
“This bill demonstrates the legislature’s commitment to economic development and 
workforce training by providing the tools and resources to allow for the continued 
investment in our people, our infrastructure, and our Massachusetts-based 
companies,” said Representative Joseph F. Wagner, House Chair of the Joint 
Committee on Economic Development and Emerging Technologies. 
 
“This legislation builds upon strategic investments made by the Baker-Polito 
Administration and is line with our overall economic development strategy,” said 
Secretary of Housing and Economic Development Jay Ash. “Our public investments 
have enabled life sciences to evolve from an emerging sector to an established global 
leader. By continuing to invest, we will maintain the vitality and competiveness of an 
industry that continues to create great jobs for our people and positively impact 
society.” 
 
“As the leading global hub for life sciences innovation and advancement, our financial 
commitment and steadfast stewardship of public investment will ensure that we 
continue to hold on to that distinction,” said Secretary of Administration and Finance 
Michael J. Heffernan. “We’re investing in programs that will attract innovative 
companies seeking to start or expand in Massachusetts and fuel the robust pipeline 
of the best-trained life sciences talent in the nation.” 
 
The five-year, $473 million bond authorization in the proposal provides capital 
funding that will enable the state to strengthen the ecosystem through collaborations 
that maximize third-party investments and sharpen the Commonwealth’s competitive 
edge.  
 
The funding will continue to be managed by the MLSC with a focus on regional 
investments that spur workforce and economic development and enrich learning and 
experiential opportunities for young people in Massachusetts. Since its inception, 
$350 million in public investments have supported R&D infrastructure and facilities 
that are available for partnership with industry. For every public dollar invested in 
these facilities, the life sciences industry has invested $1.67 alongside. This 
infrastructure creates space for new partnerships, seeds startups, and supports new 
translational research capacities. 
 
“We are grateful for the continued leadership of Governor Baker and Lieutenant 
Governor Polito and the collaborative effort with the Legislature to usher in the next 
generation of our vibrant life sciences ecosystem,” said Massachusetts Life Sciences 
Center President and CEO Travis McCready. “This spirit of partnership has allowed 
our Commonwealth to experience a near-decade of public-private partnerships in 
action with statewide impact that has positioned Massachusetts as the world’s 
leading life sciences hub. We know the entire biotech world is watching 
Massachusetts and today sends the strong message that together, we here in the 
Commonwealth have every intention to remain the number one center of life 
sciences innovation in the world.” 
 
“The reason Massachusetts is the best place in the world for life sciences is because 
government is a true partner. MassBio and our members applaud Governor Baker, his 
Administration, and the Legislature for looking carefully at the results of the first life 
sciences initiative and concluding that the state can make a real difference – to our 
economy, to employees, and to patients around the world,” said MassBio President 
and CEO Robert K. Coughlin. “We are committed to working with the Administration 
and the Massachusetts Life Sciences Center to ensure this new life sciences initiative 
keeps Massachusetts on top, benefits workers at all levels, and brings new 
opportunities across the state.” 
 
Strategic priorities for the initiative include strengthening investments in human 
capital to fortify the state’s skilled workforce pipeline, expanding opportunities for 
companies to access both private investment capital and dynamic public 
infrastructure resources, developing new scientific innovations that deliver higher 
outcome, affordable therapies to patients, and leading the convergence revolution in 
digital health, biopharma, medical devices and engineering. 
 
In addition to new capital authorization for the MLSC, the legislation extends and 
expands the authorization of a key state tax credit that fuels job growth. The proposal 
permits the MLSC to extend the tax credit to December 31st, 2028 and increases the 
MLSC’s current annual statutory cap up to $30 million on tax credit awards, totaling 
$150 million over five years. 
 
The tax incentive program provides a cost-effective way of attracting new and 
relocating companies to the Commonwealth while also ensuring that the state retains 
current commercial activity and captures investments from future growth. To date, 
207 awards have been authorized under this program, representing $181 million in 
incentives in creating more than 8,800 net new jobs across the Commonwealth and 
maintaining them over a 5-year period. The program’s track record shows that once 
incentives anchor job creation, companies will exceed their growth projections by 
larger margins, further leveraging the state’s incentive awards.  
 
“We are committed to supporting students pursuing education and training in the life 
sciences,” said Bunker Hill Community College President Pam Eddinger. “We are 
grateful for the support from Massachusetts Life Sciences Center, proud of our 
students and graduates participating in the biomedical and biotechnology fields, and 
pleased that the state will continue its substantial support, translating into a more 
vibrant life sciences sector.” 
 
“This bill ensures continued growth in our economy and advances biomedical 
research while affirming Massachusetts strong commitment to life sciences. 
Importantly, it continues funding for the Massachusetts Life Sciences Center which is 
critical to our work at Dana-Farber. Working together, we are truly pushing the pace 
of progress in cancer science,” said Laurie H. Glimcher, president and chief executive 
officer of Dana-Farber Cancer Institute. 
 
“Sanofi Genzyme has deep roots in Massachusetts and today we are the largest life-
science employer in the Commonwealth,” said Bill Sibold, head of Sanofi Genzyme. 
“We have seen this innovative ecosystem grow from the earliest days to become the 
global center of our industry. Simply put there is no better place in the world for a life 
science company to locate, grow and thrive than Massachusetts.  This legislation 
invests in the success we’ve had and will signal to the world that Massachusetts will 
continue to be the center of the life science industry.” 
 
“As a company that has grown up in Massachusetts’ world-class innovation 
ecosystem, Vertex is proof that meaningful investments in the future of our industry 
will result in life-changing medical advancements,” said Dr. Jeffrey Leiden, chairman, 
president and chief executive officer of Vertex. “Governor Baker’s Administration 
has been a true champion for the life sciences, and with this continued support, I 
have no doubt that Massachusetts will continue to lead the world in biomedical 
innovation.” 
 
“As a result of the state’s generous investment, the Massachusetts scientific 
community has access to a new multi-institutional facility in which to study how drugs 
are evaluated and speed the introduction of safe and effective new medicines,” said 
Peter Sorger, professor of systems pharmacology and director of the MLSC-
supported Lab of Systems Pharmacology. “We deeply appreciate the Baker-Polito 
Administration's making the key investment needed for an innovative new alliance 
among physician-scientists, BioPharma and patient advocates aimed at advancing 
precision medicine, strengthening the state's human and intellectual capital and 
benefiting patients across the globe.” 
 
About the Massachusetts Life Sciences Center 
The Massachusetts Life Sciences Center (MLSC) is an economic development 
investment agency dedicated to supporting the growth and development of the life 
sciences in Massachusetts, home to the most verdant and productive life sciences 
ecosystem in the world.  Through public-private funding initiatives, the MLSC 
supports innovation, research & development, commercialization, and manufacturing 
activities in the fields of biopharma, medical device, diagnostics, and digital 
health.  Since its creation in 2007, the MLSC has strategically deployed over $700 
million in Massachusetts, through a combination of grants, loans, capital 
infrastructure investments, tax incentives, and workforce programs.  These 
investments have created thousands of jobs, and propelled the development of new 
therapies, devices, and scientific advancements that are improving patient health and 
well-being in Massachusetts and beyond. 
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